Upcoming Conferences for Citius Pharmaceuticals and Citius Oncology
Get ready for an exciting fall! Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) are preparing for their attendance at significant investor conferences that will take place in October 2025. This is an excellent opportunity for investors and interested parties to engage with the companies regarding their innovative advancements and product lines.
Key Conference Details
This October, Citius Pharmaceuticals and Citius Oncology will participate in several notable conferences that showcase their ongoing commitment to advancing biopharmaceutical solutions.
LD Micro Main Event XIX
One of the first events is the LD Micro Main Event XIX scheduled for October 19-21, 2025. This event is renowned for connecting investors with emerging companies in the micro-cap sector. A key highlight of this event is its participation from various industry leaders, making it a prime venue for networking and information sharing.
Maxim Growth Summit
Following LD Micro, Citius Pharmaceuticals and Citius Oncology will also be present at the 2025 Maxim Growth Summit on October 22-23, 2025. This two-day event is designed to facilitate conversations between innovators and investors, enabling discussions around growth strategies and potential investment opportunities.
Think Equity Conference
The final conference they are attending is the Think Equity Conference on October 30, 2025. This gathering will allow Citius to connect with institutional investors in a more focused one-on-one meeting format, ensuring that crucial dialogues occur around their unique offerings and future outlook.
Engagement Opportunities
Citius Pharmaceuticals and Citius Oncology encourage interested parties to schedule one-on-one meetings with their management teams during these conferences. Attendees can arrange meetings through the respective event platforms or by reaching out directly to the investor relations teams of either company.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is dedicated to the development and commercialization of critical care medications that aim to improve patient outcomes. Their late-stage pipeline includes innovative therapies like LYMPHIR, a targeted immunotherapy freshly approved by the FDA for treating cutaneous T-cell lymphoma. Additionally, they are advancing with products like Mino-Lok, an antibiotic lock solution for patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief. With significant progress in their clinical trials, particularly the successful Phase 3 Trial for Mino-Lok, Citius is poised for growth.
About Citius Oncology
Citius Oncology, Inc. (Nasdaq: CTOR), operates under the umbrella of Citius Pharmaceuticals, focusing on innovating new oncology therapies. Their primary asset, LYMPHIR, was also recently approved by the FDA and is tailored for treating adult patients with relapsed cutaneous T-cell lymphoma. Citius Oncology has identified a substantial market opportunity, projecting its initial market at over $400 million, which continues to expand. The company is proud of its strong intellectual property protections, which safeguard its innovative therapies.
Contact Information
For inquiries, you can reach out to Ilanit Allen from Citius Pharmaceuticals at 908-967-6677 x113. They are committed to fostering strong investor relations and are eager to discuss the exciting developments within their companies.
Frequently Asked Questions
What conferences are Citius Pharmaceuticals attending?
Citius Pharmaceuticals is attending the LD Micro Main Event XIX, the 2025 Maxim Growth Summit, and the Think Equity Conference.
What topics will Citius Pharmaceuticals focus on during the conferences?
The focus will be on their innovative therapies, advancements in critical care products, and growth strategies moving forward.
How can interested investors schedule meetings?
Interested investors can schedule meetings by registering through the event platforms or contacting the company’s investor relations team directly.
What is LYMPHIR?
LYMPHIR is a targeted immunotherapy recently approved for the treatment of cutaneous T-cell lymphoma, highlighting Citius Pharmaceuticals' commitment to advancing care in critical areas.
What is the significance of these conferences for the companies?
These conferences provide opportunities for Citius Pharmaceuticals and Citius Oncology to showcase their innovations, engage with investors, and potentially attract new stakeholders for their future growth.
